Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fennec Pharmaceuticals ( (TSE:FRX) ) has shared an update.
On April 21, 2026, Fennec Pharmaceuticals announced that four abstracts evaluating its otoprotective therapy PEDMARK (sodium thiosulfate injection) were accepted for presentation or publication at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago. The studies span pediatric, adolescent and adult cancer populations, including randomized and real-world data, underscoring growing clinical interest in preventing cisplatin-induced hearing loss.
The ASCO abstracts will highlight outcomes such as ototoxicity prevention in children, young adults and adults with various solid tumors, as well as feasibility, tolerability and audiometric results across different tumor types and settings. This visibility at a major oncology forum reinforces PEDMARK’s positioning as the only FDA-approved preventive therapy for cisplatin-related hearing loss and may support broader clinical adoption and guideline recognition in an area of high unmet need.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on FRX Stock
According to Spark, TipRanks’ AI Analyst, FRX is a Neutral.
The score is held back primarily by inconsistent profitability and cash flow despite strong gross margins and improving balance-sheet strength. Technicals are also weak (price below key moving averages with negative MACD). Offsetting these, the earnings call points to accelerating sales growth, improved financial flexibility (debt eliminated), and extended exclusivity to 2033, which supports a moderate—but not high—overall score.
To see Spark’s full report on FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on combating ototoxicity in cancer patients receiving cisplatin-based chemotherapy, primarily through the commercialization of its sodium thiosulfate therapy PEDMARK. The drug, approved by regulators in the U.S., European Union and U.K. (as PEDMARQSI), targets platinum-induced hearing loss in pediatric and certain adolescent and young adult populations.
Fennec has expanded its international reach through an exclusive licensing agreement with Norgine Pharmaceuticals covering Europe, the U.K., Australia and New Zealand, where PEDMARQSI is already commercially available in the U.K. and Germany. The product benefits from Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in Europe, securing several years of data and market protection in key territories.
Average Trading Volume: 958
Technical Sentiment Signal: Sell
Current Market Cap: C$310.3M
Find detailed analytics on FRX stock on TipRanks’ Stock Analysis page.